NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal (STA) Naltrexone-bupropion (prolonged release) for managing overweight and obesity

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Orexigen Therapeutics (bupropion, naltrexone)	 Allied Health Professionals Federation Board of Community Health Councils in Wales
Patient/carer groups Beat	British Cardiovascular Industry Association
BEMDA: Black and Ethnic Minority Diabetes Association	Association British National Formulary
Black Health AgencyBlood Pressure UK	 Commissioning Support Appraisals Services
 British Cardiac Patients Association British Obesity Society Cardiovascular Care Partnership UK 	 Department of Health, Social Services and Public Safety for Northern Ireland Diabetes UK Cymru
Diabetes Research & Wellness Foundation	Healthcare Improvement ScotlandMedicines and Healthcare products
Diabetes UKHEART UKHOOP UK	Regulatory AgencyNational Association of Primary CareNational Pharmacy Association
InDependent Diabetes TrustINsulin Pump Therapy	 NHS Alliance NHS Commercial Medicines Unit
Insulin PumpersMuslim Council of Great BritainNational Obesity Forum	NHS ConfederationScottish Medicines Consortium
Network of Sikh OrganisationsOvereaters Anonymous	Possible comparator manufacturers Actavis (orlistat)
 South Asian Health Foundation Specialised Healthcare Alliance 	 GlaxoSmithKline (orlistat) Roche (orlistat)
Surya FoundationWeight Concern	Teva UK (orlistat) Polovant research groups
Professional groupsAssociation for the Study of Obesity	Relevant research groupsBritish Society for Cardiovascular Research
Association of British Clinical Diabetologists	 Cochrane Heart Group Cochrane Metabolic & Endocrine
British Association for Nursing in Cardiac Care	Disorders GroupCochrane Peripheral Vascular Disease

National Institute for Health and Care Excellence Provisional matrix for the technology appraisal of Naltrexone-bupropion (prolonged release) for managing overweight and obesity Issue date: September 2016

Consultees	Commentators (no right to submit or appeal)
 British Cardiovascular Intervention Society British Cardiovascular Society British Dietetic Association British Geriatrics Society British Heart Foundation British Hypertension Society British Nutrition Foundation Dieticians in Obesity Management Faculty of Public Health Medicine National Centre for Eating Disorders National Diabetes Nurse Consultant Group National Heart Forum UK Primary Care Cardiovascular Society Primary Care Diabetes Society Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Society for Cardiological Science & Technology Society for Vascular Technology Society of Vascular Pharmacy Association United Kingdom Clinical Pharmacy Association Vascular Society TREND UK UK Health Forum 	Group Cochrane Public Health Group CORDA MRC Clinical Trials Unit National Institute for Health Research Research Institute for the Care of Older People Wellcome Trust Associated Guideline Groups National Clinical Guidelines Centre Associated Public Health Groups Public Health England Public Health Wales NHS Trust
 Others Department of Health NHS Bath and North East Somerset CCG NHS England NHS Fylde and Wyre CCG NHS England Welsh Government 	

National Institute for Health and Care Excellence Provisional matrix for the technology appraisal of Naltrexone-bupropion (prolonged release) for managing overweight and obesity Issue date: September 2016 NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.